Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

The substantial correlation between prurigo nodularis (PN) and atopic dermatitis (AD) has been highlighted by a recent ...

Parents of children with atopic dermatitis (AD, also called eczema) know that the allergic condition can mean a heightened ...

In the wake of the elimination diets, 38% of the parents reported no improvement in their child’s AD, 35% reported a 25% ...

Individuals who suffer from atopic dermatitis are three times more likely to develop anxiety, depression and sleep ...

Treatment with the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) showed a favorable long-term benefit-risk profile ...

The following is a summary of “Assessing disease control in patients with atopic dermatitis by using the atopic dermatitis ...

Occupational contact dermatitis was common among construction workers, with metals, epoxy resin, and rubber identified as common etiological sources.

A live and archived webcast of the fireside chats and presentations will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.